Dapagliflozin (DAPA) Effects in HFpEF

Inclusion Criteria:

Signed informed consent prior to any study specific procedures.
Male or female.
Symptoms of dyspnea (NYHA II-III) with no non-cardiac or ischemia explanation.
EF ≥ 50% + BMI ≥ 30 kg/m^2
Elevated pulmonary capillary wedge pressure (PCWP) during exercise (≥ 25 mmHg) ascertained at Visit 1. Patients that have consented to study procedures but do not meet this invasive criterion will be considered as screen failures and will not be randomized .

Exclusion Criteria:

Type I diabetes.
Type II diabetes with poor control (HgbA1C ≥ 10%).
Recent hospitalization (< 30 days) or revasculariation (< 90 days).
Primary cardiomyopathy (such as amyloid).
Constrictive pericarditis.
Dyspea due to primary lung disease or myoardial ischemia in the opinion of the investigator.
Severe anemia (hemoglobin < 9gm/dl.
Significant left-sided valvular heart disease (> mild stenosis, > moderate regurgitation),
Severe kidney disease (estimated GFR < 30) or liver disease,